XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 33 filers reported holding XILIO THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,040,001 | -19.5% | 1,440,759 | 0.0% | 0.08% | -10.0% |
| Q2 2023 | $3,774,789 | -17.4% | 1,440,759 | 0.0% | 0.09% | -17.4% |
| Q1 2023 | $4,567,206 | +24.6% | 1,440,759 | +5.7% | 0.11% | +23.9% |
| Q4 2022 | $3,666,142 | -7.6% | 1,362,878 | 0.0% | 0.09% | -13.7% |
| Q3 2022 | $3,966,000 | -0.4% | 1,362,878 | 0.0% | 0.10% | -12.1% |
| Q2 2022 | $3,980,000 | -52.7% | 1,362,878 | +14.4% | 0.12% | -45.3% |
| Q1 2022 | $8,421,000 | -55.8% | 1,191,094 | 0.0% | 0.21% | -51.8% |
| Q4 2021 | $19,058,000 | – | 1,191,094 | – | 0.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RiverVest Venture Management LLC | 1,441,444 | $3,041,447 | 7.52% |
| Trustees of Columbia University in the City of New York | 249,635 | $526,730 | 0.97% |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $5,822,216 | 0.90% |
| Octagon Capital Advisors LP | 2,318,500 | $4,892,035 | 0.75% |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $5,919,421 | 0.66% |
| HARVARD MANAGEMENT CO INC | 416,059 | $878 | 0.10% |
| Rock Springs Capital Management LP | 1,440,759 | $3,040,001 | 0.08% |
| Soleus Capital Management, L.P. | 226,941 | $478,846 | 0.04% |
| Artal Group S.A. | 450,000 | $950 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 110,481 | $233,115 | 0.01% |